David Zieber, | |
500 Mariner Ave, Barrigada, GU 96913-1608 | |
(671) 300-2254 | |
Not Available |
Full Name | David Zieber |
---|---|
Gender | Male |
Speciality | Audiologist |
Location | 500 Mariner Ave, Barrigada, Guam |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629566476 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
David Zieber, Po Box 326692, Hagatna, GU 96932-6011 Ph: (671) 734-3420 | David Zieber, 500 Mariner Ave, Barrigada, GU 96913-1608 Ph: (671) 300-2254 |
News Archive
Smokers who received smoking cessation counseling and used electronic cigarettes containing nicotine were more than twice as likely to successfully quit smoking compared to those who received counseling but did not use e-cigarettes, in a clinical trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
A study led by the University of Barcelona has identified the process in the brain which strengthens or weakens memories of our daily events while we sleep. According to the study published in the scientific journal The Journal of Neuroscience , the brain reactivates networks of interrelated memories during sleep, instead of doing so with isolated memories.
Most people know that regular exercise is good for your health. New research shows it may make you smarter, too.
IES, a leading national provider of electrical and communications systems and services for the commercial, industrial and residential markets, announced today that its commercial business group has been awarded a contract from Manhattan Torcon JV to install the electrical systems for the Level 4 bio-safety lab (BSL-4) replacement facility at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick in Frederick, Md.
Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.
› Verified 6 days ago